The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus

Inflammation Research

Volumn 48, Issue 5, 1999, Pages 255-261

  Cross, J T ^a   Benton, H P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoantibodies; B cells; Cytokines; SLE

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 6;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CELL ACTIVITY; CELL PROLIFERATION; HUMAN; MOUSE; NONHUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; B-LYMPHOCYTES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0033066019     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050456     Document Type: Review

References (53)

1. [1] Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 330: 1871-9.
2. [2] Drake CG, Rozzo SJ, Vyse TJ, Palmer E, Kotzin BL. Genetic contributions to lupus-like disease in (NZB × NZW) F1 mice. Immunol Rev 1995; 144: 51-74.
3. [3] Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro R. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993; 20: 731-3.
4. [4] Dayan M, Segal R, Mozes E. Cytokine manipulation by methotrexate treatment in murine experimental SLE. J Rheumatol 1997; 24: 1075-82.
5. [5] Rothenberg RJ, Graziano FM, Grandone JT, Goldberg JW, Bjarnason DF, Finesilver AG. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988; 31: 612-5.
6. [6] Segal R, Dayan M, Zinger H, Mozes E. Methotrexate treatment in murine experimental SLE: clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995; 101: 66-72.
7. [7] Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Brit J Rheumatol 1995; 34: 602-9.
8. [8] Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985; 37: 269-363.
9. [9] Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-14.
10. [10] Reninger L, Winkler TH, Kalberer CP, Jourdan M, Melchers K, Rolink AG. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB × NZW) F1 mice. J Exp Med 1996; 184: 853-61.
11. [11] Kitani A, Hara M, Hirose T, Harigai M, Suzuki K, Kawakami M, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992; 88: 75-83.
12. [12] Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunopathol 1992; 63: 10-2.
13. [13] O'Garra A, Howard M. Cytokines and Ly-1 (B1) B cells. Intl Rev Immunol 1992; 8: 219-34.
14. [14] Klinman DM, Steinberg AD. Inquiry into murine and human lupus. Immunol Rev 1995; 144: 157-93.
15. [15] Umland SP, Go NF, Cupp JE, Howard M. Responses of B cells from autoimmune mice to IL-5. J Immunol 1989; 142: 1528-35.
16. [16] Emilie D, Zon W, Fior R, Llorente L, Durandy A, Crevon M-C, et al. Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods 1997; 11: 133-42.
17. [17] Klippel JH. Systemic lupus erythematosus: demographics, prognosis, and outcome. J Rheumatol 1997; 24 (Suppl 48): 67-71.
18. [18] McMurray RW, Huffman RW, Nelson W, Walker SE. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus-a analyses of strain, gender, and age effects. Clin Immunol Immunopathol 1997; 84: 260-8.
19. [19] O'Garra A, Chang R, Go N, Hastings R, Haughton G, Howard M. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 1992; 22: 711-7.
20. [20] Reap EA, Sobel ES, Cohen PL, Eisenberg RA. Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr mice. J Exp Med 1993; 177: 69-78.
21. [21] Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. J Immunol 1991; 147: 117-23.
22. + and CD5 B cells of autoimmune NZB × NZW F1 mice. Clin Exp Immunol 1996; 106; 253-8.
23. [23] Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993; 151: 6525-6534.
24. [24] Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, et al. The essential role of B cell stimulatory factor 2 (BSF2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 332-44.
25. [25] Hirano T, Teranishi T, Lin B, Onoue K. Human helper T cell factor(s) IV: demonstration of a human late-acting B cell differentiation factor acting on staphylococcus aureus Cowan I-stimulated B cells. J Immunol 1984; 133: 798-802.
26. [26] Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994; 94: 585-91.
27. [27] Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Int J Cancer 1996; 65: 498-505.
28. [28] Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Eto S, et al. Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus. J Immunol 1988; 141: 3043-9.
29. [29] Chan EY-T, Lau C-S, Zola H. Expression of IL-2R, IL-4R, IL-6R on Peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study. J Clin Pathol 1994; 49: 660-3.
30. [30] Moore KW, O'Garra A, deWaal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-90.
31. [31] Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 Mice. J Exp Med 1994; 179: 305-10.
32. [32] Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988; 241: 825-8.
33. [33] Hibi M, Murakami M, Saito M, Hirano T, Toga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149-57.
34. [34] Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K., Yamanishi K, et al. IL-6 induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260: 1808-10.
35. [35] Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, et al. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 1994; 269: 23286-9.
36. [36] Lemay S, Mao C, Singh AK. Cytokine gene expression in the MRL/lpr model of lupus nephritis. Kidney Int 1996; 50: 85-93.
37. [37] Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-90.
38. [38] Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. J Exp Med 1989; 170: 2081-95.
39. [39] Hsu DH, Moore KW, Spits H. Differential effects of interleukin-4 and -10 on interleukin-2 induced interferon γ synthesis and lymphokine-activated killer activity. Int Immunol 1992; 4: 563-9.
40. [40] Rousset F, Garcia E, Defrance C, Peronne DH, Hsu R, Kastelein K, et al. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890-3.
41. [41] Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, et al. Interleukin 10 (IL-10), a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Fxp Med 1990; 172: 1625-31.
42. [42] de Waal Malefyt F, Abrams J, Bennett B, Figdor C, de Vries J. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-20.
43. [43] Mongan AE, Ramdahin S, Warrington RJ. Interleukin 10 response abnormalities in systemic lupus erythematosus. Scand J Immunol 1997; 46: 406-12.
44. [44] Jacob CO, McDevitt HO. Tumor necrosis factor-α in murine autoimmune "lupus" nephritis. Nature 1988; 331: 356-8.
45. [45] Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989; 52: 421.
46. [46] Tan JC, Indelicato SR, Narula SK, Zavodny PJ, Chou CC. Characterization of interleukin-10 receptors on human and mouse cells. J Biol Chem 1993; 268: 21053-9.
47. [47] Liu Y, Wei SH-Y, Ho AS-Y, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994; 152: 1821-9.
48. [48] Hayakawa K, Hardy RR, Parks DR, Herzenberg LA. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med 1983; 157: 202-18.
49. [49] Hayakawa K, Hardy RR, Herzenberg LA. Peritoneal Ly-1 B cells: genetic control, autoantibody production, increased lambda light chain expression. Eur J Immunol 1986; 16: 450-6.
50. [50] Sherr DH, Dorf ME, Gibson M, Sidman CL. Ly-1 B Helper cells in autoimmune "viable motheaten" mice. J Immunol 1987; 139: 1811.
51. [51] Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994; 56: 1-26.
52. [52] Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-γ receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995; 25: 6-12.
53. [53] Raz E. Dudler J, Lotz M, Baird SH, Berry CC, Eisenberg RA, et al. Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 1995; 4: 286-92.